2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130801
    5-Hydroxy-2'-deoxyuridine 5168-36-5 99.77%
    5-Hydroxy-2'-deoxyuridine (5-OHdU) is a major stable oxidation product of 2'-Deoxycytidine. 5-Hydroxy-2'-deoxyuridine can be incorporated into DNA in vitro by DNA polymerase.
    5-Hydroxy-2'-deoxyuridine
  • HY-131007
    FFN270 hydrochloride 2341841-05-0 99.0%
    FFN270 hydrochloride, a fluorescent tracer of norepinephrine, is a fluorescent substrate of the norepinephrine and vesicular monoamine transporters. FFN270 hydrochloride exhibits two resolved absorption/excitation maxima depending on solvent pH (FFN270 ex: 320 nm or 365 nm, em: 475 nm) and can function as ratiometric fluorescent pH-sensors.
    FFN270 hydrochloride
  • HY-131303
    Heptadecanoyl Coenzyme A 3546-17-6
    Heptadecanoyl Coenzyme A (Heptadecanoyl-CoA), long-chain acyl-coenzymes A (acyl-CoAs) (LCACoA), is an intermediate in lipid metabolism. Heptadecanoyl Coenzyme A can be used for the research of glucose metabolism.
    Heptadecanoyl Coenzyme A
  • HY-135065
    3-Iodothyronamine hydrochloride 788824-64-6 99.5%
    3-Iodothyronamine (hydrochloride) is an endogenous and rapid-acting derivative of thyroid hormone. 3-Iodothyronamine potently activates an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale. 3-Iodothyronamine can be used for the research of congestive heart failure.
    3-Iodothyronamine hydrochloride
  • HY-135484
    NDSB-195 160255-06-1 99.93%
    NDSB-195 is protein stabilizer that enhances the dynamics of the β4-α2 loop of ubiquitin. NDSB-195 stabilizes Saccharomyces cerevisiae ubiquitin against guanidium chloride denaturation, increasing the onset temperature of heat denaturation in the presence of the denaturant.
    NDSB-195
  • HY-135680
    I-OMe-Tyrphostin AG 538 1094048-77-7 98.03%
    I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells.?I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50?of 1 μM.
    I-OMe-Tyrphostin AG 538
  • HY-139040
    2-(Tetradecylthio)acetic acid 2921-20-2 ≥98.0%
    2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation.
    2-(Tetradecylthio)acetic acid
  • HY-139077
    SCD1 inhibitor-3 1282606-48-7 98.24%
    SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.
    SCD1 inhibitor-3
  • HY-141842
    GLP-1R modulator L7-028 2648317-95-5 99.47%
    GLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 11.01 ± 2.73 μM).
    GLP-1R modulator L7-028
  • HY-144034
    GLP-1R agonist 3 2428640-18-8
    GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1).
    GLP-1R agonist 3
  • HY-14601R
    Pioglitazone hydrochloride (Standard) 112529-15-4 99.89%
    Pioglitazone (hydrochloride) (Standard) is the analytical standard of Pioglitazone (hydrochloride). This product is intended for research and analytical applications. Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
    Pioglitazone hydrochloride (Standard)
  • HY-150687
    ZINC12409120 1010888-06-8 99.95%
    ZINC12409120 is a high selective ERK inhibitor. ZINC12409120 acts on disrupting FGF23:α-Klotho interaction to inhibit ERK activity with an IC50 of 5.0 μM.
    ZINC12409120
  • HY-15209R
    Repaglinide (Standard) 135062-02-1 99.96%
    Repaglinide (Standard) is the analytical standard of Repaglinide. This product is intended for research and analytical applications. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus.
    Repaglinide (Standard)
  • HY-153335
    Enpp-1-IN-16 2289739-47-3 98.46%
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders.
    Enpp-1-IN-16
  • HY-153754
    Phosphatidylcholine transfer protein inhibitor-1 379723-99-6 98.01%
    Phosphatidylcholine transfer protein inhibitor-1 is a derivative of phosphatidylcholine transfer protein (PC-TP) inhibitor. Phosphatidylcholine transfer protein inhibitor-1 can be used for the research of obesity, type 2 diabetes, non-alcoholic fatty liver disease.
    Phosphatidylcholine transfer protein inhibitor-1
  • HY-154823
    Gcase activator 2 2759897-35-1 99.62%
    Gcase activator 2 (compound 14), a pyrrolo[2,3-b]pyrazine, is alos a β-Glucocerebrosidase (GCase) activator (EC50=3.8 μM). Gcase activator 2 induces GCase dimerizatio (both K-type and V-type). And Gcase activator 2 has low metabolic clearance in human and mouse.
    Gcase activator 2
  • HY-156968
    GLP-1 receptor agonist 14 3011682-51-9 98.78%
    GLP-1 receptor agonist 14 (compound 474) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders.
    GLP-1 receptor agonist 14
  • HY-161321
    PTP1B-IN-24 2221707-61-3 98.46%
    PTP1B-IN-24 (Compound 9) is a reversible PTP1B inhibitor with an IC50 value of 1.4 μM, and PTP1B-IN-24 can enhance the thermal stability of PTP1B. PTP1B-IN-24 can restore PA- (HY-N0830) induced insulin resistance by increasing the phosphorylation levels of IRS1 and AKT.
    PTP1B-IN-24
  • HY-161759
    MS152 3107476-89-8 99.36%
    MS152 is an oral bioactive inhibitor of EHMT2/G9a. MS152 reactivats maternally silenced Prader-Willi syndrome (PWS) genes in brain and liver tissues of PWS mouse models.
    MS152
  • HY-175869
    Ferroptosis-IN-22 3096878-87-1 99.97%
    Ferroptosis-IN-22 is a selective ferroptosis inhibitor by targeting NCOA4 and disrupting its interaction with ferritin with an EC50 of 520 nM and a Kd of 0.78 μM. Ferroptosis-IN-22 has a strong inhibitory activity against ferroptosis induced by multiple ferroptosis inducers (RSL3 (HY-100218A), Erastin (HY-15763), ML210 (HY-100003), FIN56 (HY-103087)), but does not inhibit necrosis induced by H2O2 or apoptosis induced by STS (HY-15141). Ferroptosis-IN-22 effectively ameliorates Concanavalin A (HY-P2149)-induced acute liver injury. Ferroptosis-IN-22 can be used for the study of ferroptosis-related diseases.
    Ferroptosis-IN-22
Cat. No. Product Name / Synonyms Application Reactivity